BioSpace News Archive

OnPoint, a group of privately held augmented reality (AR) technology companies pioneering AR guidance for multiple verticals including spine, neurosurgical, and orthopedic surgical procedures, including robotic procedures, today announced that it will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023.

AcuityMD has expanded its partnership with Olympus Corporation, a top 20 MedTech company that delivers advanced diagnostic, therapeutic, and minimally invasive procedures to healthcare professionals.

Calidi Biotherapeutics, Inc. today announced that Allan Camaisa, CEO and Chairman of the Board, and Stephen Thesing, Chief Business Officer, will participate in a fireside chat at the upcoming Baird Global Healthcare Conference on Wednesday, September 13, 2023, at 7:55 a.m. ET.

Pyramid, a leading large molecule drug product contract development and manufacturing organization (“CDMO”), announced the appointment of Amy Driver as Vice President of Business Development and Peter Buzy to the Board of Directors.

2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh.

Panavance Therapeutics Inc . today announced publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight.

Arcutis Biotherapeutics, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older.

Anavex Life Sciences Corp. today announced the appointment of Prof. Dr. Marwan N Sabbagh, MD, as Chairman of the Scientific Advisory Board.